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ABSTRACT
Objective: Our study estimated the cost-effectiveness of
pharmacologic treatment of obesity in combination with a
low-calorie diet in The Netherlands.
Methods: Costs and effects of a low-calorie diet-only inter-
vention and of a low-calorie diet in combinationwith 1 year of
orlistat were compared to no treatment. The RIVM Chronic
Disease Model was used to project the differences in quality
adjusted life years (QALYs) and lifetime health-care costs
because of the effects of the interventions on body mass index
(BMI) status. This was done by linking BMI status to the
occurrence of obesity-related diseases and by relating quality
of life to disease status. Probabilistic sensitivity analysis was
employed to study the effect of uncertainty in the model
parameters. In univariate sensitivity analysis, we assessed how
sensitive the results were to several key assumptions.
Results: Incremental costs per QALY gained were €17,900
for the low-calorie diet-only intervention compared to no
intervention and €58,800 for the low-calorie diet + orlistat
compared to the low-calorie diet only. Assuming a direct
relation between BMI and quality of life, these ratios
decreased to €6000 per QALY gained and €24,100 per QALY
gained. Costs per QALY gained were also sensitive to
assumptions about long-term weight loss maintenance.
Conclusions: Cost-effectiveness ratios of interventions
aiming at weight reduction depend strongly on assumptions
regarding the relation between BMI and quality of life. We
recommend that a low-calorie diet should be the ﬁrst option
for policymakers in combating obesity.
Keywords: cost-effectiveness analysis, modeling, obesity,
orlistat.
Introduction
Obesity is a major cause of morbidity and mortality
[1,2]. The prevalence of overweight, deﬁned as a body
mass index (BMI)25 kg/m2, is increasing worldwide.
Reversing this trend is a major health policy aim in
many countries [3]. It has been estimated that in
The Netherlands overweight causes yearly 40,000 new
cases of heart disease, type 2 diabetes, and cancer, and
is responsible for approximately 7% of all mortality
[4]. Successful treatment of obesity thus may dramati-
cally lower the burden of disease.
To be effective, obesity treatment should aim to
achieve a modest weight loss (5–15%) that can be
sustained in the long term [5,6]. Treatment options
include lifestyle programs, such as a low-calorie diet,
exercise, behavioral therapy, pharmacologic treatment,
and even surgery. Generally, an integrated, multimodal,
approach is recommended, such as a combination of
lifestyle programs and pharmacologic treatment [7].
The most frequently used weight-reducing drugs are
orlistat and sibutramine.Many studies have shown that
pharmacologic treatment of obesity in combination
with life-style changes achieves a modest weight loss
[8]. Moreover, economic evaluations mostly concluded
that pharmacologic treatment of obesity is cost-
effective compared to lifestyle changes only. Reported
cost-effectiveness ratios range from approximately
€10,000 to €35,000 per quality adjusted life year
(QALY) gained [9–12]. It should be noted, however,
that in all of these studies effects on BMI were directly
translated into changes in quality of life [13,14]. In our
study, by contrast, we aimed to assess the cost-effec-
tiveness of pharmacologic treatment of obesity in com-
binationwith a low-calorie diet by linking quality of life
to the occurrence of obesity-related diseases rather than
assuming a direct effect of obesity on quality of life. This
way, gains in length and quality of life can be ascribed to
the prevention of chronic diseases such as diabetes,
cardiovascular disease, and osteoarthritis [15].
Methods
Incremental cost-effectiveness ratios (ICERs) were ﬁrst
calculated by comparing treatment with orlistat in
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combination with a low-calorie diet, and, second, by
comparing a low-calorie diet only to no treatment at
all. The target population consisted of all Dutch indi-
viduals between 20 and 70 years of age with a BMI
30 who were not being treated for obesity. We chose
“no treatment” as comparator because it best reﬂects
current primary care practice in The Netherlands. A
recent nationwide study showed that 22% of patients
diagnosed with obesity in primary care receive phar-
macologic treatment, although only 5% are referred to
a dietician [16]. All other patients received no treat-
ment, or were given only informal lifestyle advice of
low intensity [16]. It was assumed that those who did
not respond to the orlistat treatment discontinued
treatment after 3 months [8]. Nonreponse to orlistat
treatment was deﬁned as a weight loss of less than 5%
within the ﬁrst 3 months of treatment. Based on the
literature, we used a nonreponse rate of 50% [8]. By
evaluating the interventions from a health-care per-
spective, we assumed that the interventions would be
paid for by parties belonging to the health-care system.
In accordance with the Dutch guidelines for pharma-
coeconomic research, effects and costs were discounted
at a yearly rate of 1.5% and 4.0%, respectively
[17,18].
We employed the RIVM Chronic Disease Model
(CDM) to translate from weight loss as a result of
treatment to life years and QALYs gained, and to
calculate lifetime health-care costs [15,19–22]. To cal-
culate ICERs, discounted yearly differences in out-
comes between the intervention and the current
practice scenarios were added over the time interval
modeled of 80 years. This resulted in net present
values for life years gained, QALYs gained, and incre-
mental health-care costs. All cost data were presented
in euros, for the price level of 2005. Costs taken into
account were the costs of the interventions, the savings
(negative costs) because of a reduced incidence of
obesity-related diseases as well as the costs of unre-
lated diseases occurring during life years gained [21].
Costs of the Interventions
Table 1 presents the intervention costs for the orlistat
plus low-calorie diet intervention. These costs were
calculated by using a so-called bottom-up method as
advocated in the Dutch pharmacoeconomic guidelines
[23]. This means that ﬁrst the intervention was ana-
lyzed in detail to identify all of its elements and thereby
the resources used. The units of resources used were
then multiplied by standardized unit costs. In calculat-
ing the costs, it was assumed that patients visit the
dietician every 3 months, and that nonresponders to
orlistat treatment stop after two visits. Furthermore,
as part of the low-calorie diet intervention, it was
assumed that each patient was provided a food diary.
The medication costs per patient were determined on
the basis of national reference prices (GIP, http://www.
gipdatabank.nl; CVZ, http://www.medicijnkosten.nl).
Orlistat tablets are taken three times daily.
Effects of the Interventions on Weight
Estimates of weight loss because of the two interven-
tions were based on meta-analyses published in the
international literature. The weight loss resulting from
the interventions after 1 year [8,24] was translated
into long-term weight loss by assuming that 23% of
the weight loss achieved after 1 year can be maintained
in the long run [25].
Effects of Weight Loss on Life Years, QALYs, and
Lifetime Health-Care Costs
The health gains and the effects of long-term weight
loss on lifetime health-care costs were estimated using
the CDM [15,19,21,22,26,27]. As mentioned above,
the CDM is a dynamic population model that
describes the life course of cohorts in terms of transi-
tions between risk factor classes and disease states
over time. BMI is modeled as a discrete variable
divided intro three classes: 18.5  BMI < 25 (normal),
25  BMI < 30 (overweight), BMI  30 (obesity).
Obesity-related diseases in the CDM are coronary
heart disease, stroke, diabetes, osteoarthritis, low back
pain, and some forms of cancer [15]. The link between
risk factors and diseases is modeled by assigning rela-
tive risks of disease incidence to each risk factor class.
Because the presence of a disease increases mortality
rates, risk factor levels ultimately inﬂuence mortality.
To estimate incidence, prevalence, and mortality rates,
three types of data sources were used: general practi-
tioners’ registrations, national registries, and popula-
tion surveys. For cancers, national registries were
considered the most reliable source. Data for most
Table 1 Costs per patient during year of intervention (2005 euros)
Type of costs Units Unit price Costs
GP time 15 min 2.07 20.70–41.40
Dietician time 180 min 0.85 102–204
Food diary 1 manual 12.85 12.85
Orlistat (three tablets per day)
Minimum only 3 months 50% 45 (45 tablets of 120 mg) 270
Maximum for 12 months 50% 1080
GP, general practitioner.
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noncancerous diseases were based on a combination of
up to ﬁve different general practitioners’ registrations
or other medical care registrations. Relative risks
of morbidity and mortality for BMI were based on
several observational studies. Details on the methods
and input data employed in the CDM have been dis-
cussed in depth elsewhere [15].
Differences in QALYs and lifetime health-care costs
because of the interventions were assessed by translat-
ing long-term weight loss into differences in the preva-
lence of obesity. This was done by ﬁrst subtracting the
average long-term weight loss achieved by the inter-
vention from the weights of each of the individuals
making up the target population. Next, the resulting
weights were converted to BMI values, allowing com-
parison between prevalences before and after the inter-
ventions. For the conversion from weight to BMI, we
used the weight and length distributions reported in
the so-called second Dutch general practice study [16].
To compute health effects in terms of QALYs, the
CDM couples disability weights from the Dutch
Burden of Disease Study [28] to disease prevalence
rates [15,20,29]. Disability weights reﬂect the severity
and impact of a disease relative to death and optimal
health, deﬁned as absence of disability or disease,
and ranges from 0 (no disability) to 1 (death) [30]. The
Dutch Burden of Disease Study estimated disability
weights for 48 different disease categories, using the
person trade off method [28]. Obesity itself was not
considered a disease, and therefore, improvements in
BMI status only result in improvements in quality of
life if BMI-related diseases are avoided. For diseases
causally related to BMI, we used the CDM to estimate
diseases prevalence rates as a function of time. To
capture the impact on quality of life of diseases not
related to obesity during life years gained, we used age-
and gender-speciﬁc prevalence rates as reported in the
Dutch Burden of Disease Study [31]. Cost-of-illness
data from the Netherlands for the year 2003 [32]
served to estimate health-care expenditure conditional
on disease status and age [20,21]. Annual disease costs
per patient were multiplied by the projected future
prevalence numbers for each obesity-related chronic
disease in the model. Costs of all other—obesity-
unrelated—diseases, incurred during life years gained,
were calculated as the product of the numbers of “sur-
vivors” and the category of “remaining costs.” These
latter equal the difference between total health-care
costs and the costs of the obesity-related diseases incor-
porated in the model. They include, for instance, the
costs of mental and behavioral disorders. Finally, these
two categories of costs, one related and the other un-
related to the risk factor under study, were added to
estimate annual costs.
Probabilistic Sensitivity Analysis
We employed probabilistic sensitivity analysis (PSA)
and ran the model 500 times to assess the effect of
uncertainty regarding some of the input parameters on
outcomes. Results of the PSA are displayed in a costs
versus effects plane and a cost-effectiveness acceptabil-
ity curve [33]. Table 2 describes the stochastic input
data used in the PSA.
Sensitivity Analyses
Besides the PSA, we carried out a series of univariate
sensitivity analyses to investigate the robustness of our
results to some key parameters and assumptions.
Mean incremental costs per QALY were calculated for
the following scenarios:
• Quality of life exclusively determined by BMI
status: in this scenario, quality of life did not
depend on disease but solely on BMI status. For
this scenario, the study by Hakim et al. [13] was
employed, which estimated that for each unit
increase in BMI quality of life decreases by 0.017
points;
• Fifty percent weight loss maintenance in both
interventions: in this scenario, it was assumed that
for both interventions 50% of the weight loss after
1 year is maintained in the long run;
Table 2 Stochastic parameters
Low-calorie diet-only intervention Low-calorie diet + orlistat intervention
GP time Uniform distribution:
10–20 min
Uniform distribution:
10–20 min
Dietician time Uniform distribution:
120–240 min
Uniform distribution:
120–240 min
Weight loss (in kg) after one year due to low-calorie diet [26] Normal distribution
Mean: 3.2
SD: 0.54
Normal distribution
Mean: 3.2
SD: 0.54
Weight loss (in kg) after one year due to orlistat [8] Normal distribution
Mean: 2.89
SD: 0.32
Proportion successful weight loss maintenance [27] Normal distribution
Mean: 0.23
SD: 0.015
Normal distribution
Mean: 0.23
SD: 0.015
GP, general practitioner.
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• One hundred percent weight loss maintenance in
both interventions: in this scenario, it was assumed
that for both interventions 100%of the weight loss
after 1 year is maintained in the long run;
• Fifty percent weight loss maintenance in the orl-
istat intervention: in this scenario, it was assumed
that 50% of the initial weight loss after 1 year
because of the orlistat intervention is maintained
in the long run. Weight loss maintenance because
of low-calorie diet treatment is the same as in the
base case analysis;
• Target population with a BMI between 30 and 35:
in this scenario, only persons with a BMI between
30 and 35 were offered the interventions;
• Excluding costs of unrelated medical care: in this
scenario, incremental medical costs of diseases not
related to obesity incurred during life years gained
were excluded;
• Excluding costs of unrelated medical care and
savings in BMI-related diseases: in this scenario,
only the 1-year costs of the diet and orlistat inter-
ventions were included. Savings in costs because
of a reduction in BMI-related diseases as well as
costs of unrelated medical care were excluded.
Results
Figure 1 presents histograms displaying the propor-
tions of individuals in the target population who
move from the obese to the overweight class because
of the diet respectively the diet + orlistat interventions.
On average, this proportion equals 1% for the
diet-only intervention and 1.9% for the diet + orlistat
intervention.
Figure 2 presents average differences in diabetes
and osteoarthritis prevalence because of the diet-only
intervention compared to no care. It illustrates the
importance of the factor time in evaluating the effects
of the interventions. After the intervention, the preva-
lence numbers of diabetes and of osteoarthritis ﬁrst
decrease because of a reduction in the incidence of
these diseases. In the long run, however, prolonged life
expectancy results in an increase of the prevalence of
osteoarthritis. Ultimately, differences in prevalence
over time vanish as more of the target population die.
Table 3 shows incremental life years, QALYs,
and health-care costs as well as ICERs for the target
population.
Mean incremental costs per QALY were €17,900
for the low-calorie diet compared to no care and
€58,800 for low-calorie diet + orlistat compared to the
low-calorie diet only. Nevertheless, a low-calorie diet
alone results in more modest health gains than a low-
calorie diet in combination with orlistat.
To represent uncertainty around the ICER, Figure 3
displays a costs (differences in intervention + lifetime
health-care costs) and effects (QALYs gained) plane for
low-calorie diet and low-calorie diet + orlistat com-
pared to usual care, for different values of the input
parameters as speciﬁed in Table 2.
Figure 2 Average differences in diabetes and
osteoarthritis prevalence over time because of
the diet-only intervention.
Figure 1 Histograms of the proportions of individuals in the target
population who move from the obese to the overweight class because of
the diet respectively the diet + orlistat interventions.
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Figure 4 displays the cost-effectiveness acceptability
curve for usual care, low-calorie diet, and low-calorie
diet+orlistat.
Figure 4 indicates that for low monetary values
placed on a QALY, neither a low-calorie diet nor a
low-calorie diet + orlistat is likely to be cost-effective.
For values placed on a QALY between approximately
€18,000 and €58,000, low-calorie diet alone is prob-
ably the most cost-effective. For values higher than
€58,000, low-calorie diet + orlistat is probably the
most cost-effective option.
Table 4 shows results of the sensitivity analyses.
Table 4 clearly demonstrates that if quality of life
increases linearly as a function of weight loss, although
it is further assumed that the weight loss achieved lasts
for a life time, ICERs decrease dramatically. In our
base case analysis, ICERs are much higher due a time
lag between the intervention and the effects on disease
incidence. Moreover, we further assumed that quality
of life decreases at older ages. ICERs are also sensitive
to assumptions about long-term weight loss mainte-
nance. If weight loss after 1 year can be sustained in
the long run, ICERs decrease to €8100 and €23,400
per QALY gained for the two interventions. The ICER
for the low-calorie diet-only intervention was €13,000
per QALY gained when only the intervention costs
were taken into account. Including also the difference
in costs of obesity-related diseases in future life years,
the ICER for the low-calorie diet-only was €12,000 per
QALY gained. Table 4 demonstrates that taking into
account differences in lifetime medical costs increases
cost-effectiveness ratios by roughly €5000 per life year
or QALY gained.
Discussion and Conclusions
Obesity increases the risk of developing diseases such
as diabetes and coronary heart disease. Prevention of
obesity, by decreasing the incidence of such diseases,
will therefore result in increases in life expectancy
and decreases in health-care costs. Nevertheless, these
life years gained come at a price. Later in life, people
suffer other diseases that decrease quality of life and
increase health-care utilization. In the simulation
model employed, we estimated these effects by cou-
pling disease incidence rates to changes in risk factor
levels. In turn, having a particular disease or not deter-
mines quality of life and health-care costs. Using this
approach, modeling the cost-effectiveness of treatment
with orlistat in combination with a low-calorie diet
resulted in an ICER of €58,800 per QALY gained. The
cost-effectiveness of a low-calorie diet-only interven-
tion was estimated at €17,900 per QALY gained.
Our modeling exercise resulted in a higher cost-
effectiveness ratio for the treatment of obesity through
a low-calorie diet in combination with orlistat than
what has been reported in previous studies. One of the
explanations for this difference lies in the methods
Table 3 Estimates of total costs and effects of low-calorie diet and low-calorie diet in combination with Orlistat (95% conﬁdence
interval) for the target population (1,138,000 subjects)
Low-calorie diet only Low-calorie diet in combination with orlistat
QALYs gained 17 31
*1000 (discount rate 1.5%) (11–23) (25–39)
Life years gained 18 34
*1000 (discount rate 1.5%) (12–25) (27–41)
Incremental health-care costs 302 1136
*€1000,000 (discount rate 4%) (236–373) (1065–1209)
(Incremental intervention costs + incremental
lifetime health-care costs)/(life years gained)*
€16,400 €53,600
(Incremental intervention costs + incremental
lifetime health-care costs)/(QALYs gained)*
€17,900 €58,800
*Costs discounted at 4% and effects discounted at 1.5%.
QALYs, quality adjusted life years.
Figure 3 Incremental costs and effects of low-
calorie diet and low-calorie diet + orlistat com-
pared to usual care for the target population.
QALYs, quality adjusted life years.
Cost-Effectiveness of a Low-Calorie Diet and Orlistat 1037
used to calculate QALYs. Studies by Lacey and Hertz-
man [12,34] used a much shorter time horizon
(5 years) and assumed a direct effect of decreases in
BMI on improvements in quality of life based on a
earlier study by Hakim et al. [13]. They thus assumed
instantaneous improvements in quality of life as a
result of the intervention. In our model, we only
assumed improvements in quality of life indirectly,
namely through a reduced risk of the development of
obesity-related diseases. The particular methodology
we used accounts for much smaller gains in quality of
life during the life years that would have been lived
also without the intervention [15]. Furthermore, we
took into account the fact that quality of life generally
decreases with advancing age. This is important,
because obviously most of the life years gained occur
at advanced ages. Similar to Roux et al. [9], we used a
lifetime perspective and tracked lifetime costs. We also
assumed the same degree of long-term weight loss
maintenance. Nevertheless, their study, in contrast to
ours, assumed a direct relation between BMI level and
quality of life. This may explain the large differences
they reported between costs per life year gained and
costs per QALY gained. We performed a health-
economic evaluation from the health-care perspective
and concentrated on effects of interventions on health
and lifetime health-care costs and compared these with
intervention costs. This is relevant information for the
health-care decision-maker, who may be primarily
concerned with health-care costs [35,36]. We did not
include effects on the cost because of lost productivity
and we did not take into account effects on informal
care. Including these aspects would imply a societal
perspective to be used in cost-effectiveness analysis to
demonstrate the broader societal costs and beneﬁts
from the interventions [37]. Such a broader perspec-
tive is normally advocated in economic evaluations,
because it gives a complete picture of welfare changes
in society associated with a particular intervention
[38]. A next step therefore would be to assess the
cost-effectiveness of these interventions from a societal
perspective.
The strength of the model presented is that the
causal effects of changes in BMI level on quality of life
and health-care costs were estimated by coupling
health-care costs and quality of life to diseases related
to obesity instead of coupling them directly to BMI
status. We only included diseases for which a causal
relation to obesity has been established [1]. A limita-
tion of our model is that three different BMI classes
were used with average relative risks computed using
the BMI distribution over these classes in the Nether-
lands. This is a rather crude classiﬁcation, which may
not be sensitive enough to capture small differences in
weight. Assuming that BMI is a continuous risk factor
this means that we have underestimated health gains
for persons with extreme obesity and overestimated
health gains for persons with moderate obesity. To
what extent this approach results in biased estimates
of health gains and therefore in biased estimates of
the ICER is difﬁcult to assess. For this to completely
balance out would require an assumption that the sum
Figure 4 Cost-effectiveness acceptability cur-
ves for usual care, low-calorie diet, and low-
calorie diet + orlistat. QALY, quality adjusted life
year.
Table 4 Results of sensitivity analysis on ICER (costs discounted at 4% and effects discounted at 1.5%)
Low-calorie diet only
Low-calorie diet in
combination with orlistat
Base case €17,900 €58,800
Quality of life exclusively determined by BMI status €6,000 €24,100
100% weight loss maintenance both interventions €8,100 €23,400
50% weight loss maintenance both interventions €11,000 €33,300
100% weight loss maintenance orlistat €17,800 €18,700
Target population BMI between 30 and 35 €13,400 €51,100
Excluding costs of unrelated medical care €12,100 €53,000
Excluding costs of unrelated medical care and savings in BMI-related diseases €13,300 €53,900
BMI, body mass index; ICER, incremental cost effectiveness ratio.
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of the smaller continuous health effects for all those
who lose weight is about equal to the sum of the
threshold effects for those who cross the 30 BMI
thresholds. This could work, more or less, if the ben-
eﬁts of weight loss are roughly linear with changes in
BMI. Nevertheless, the literature tends to suggest that
health risks increase quadratically with BMI [39,40].
On the other hand, the BMI distribution is known to be
heavily skewed, meaning that there are more persons
with a BMI of 31 than of 32 and so on. The effect of the
skewness of the distribution would be to counteract the
bias because of the nonlinearity of the relation between
BMI and health risks, as there would be correspond-
ingly more individuals for whom the beneﬁts of weight
loss would be underestimated than overestimated in the
direction of being under-estimates of the effects of
weight loss. Another crucial assumption was the esti-
mate of the long-term effectiveness of interventions on
BMI. In this study, it was assumed that 23% of the
weight loss was maintained in the long run. If we did
not take the relapse into account, costs would be sub-
stantially lower: €8100 per QALY gained for low-
calorie diet only, and €23,400 per QALY gained for a
low-calorie diet in combination with orlistat. It has
been shown that longer and active follow-up can
prevent weight regain [41]. Nevertheless, this would
also involve additional costs. Finally, we neglected any
possible side effects of orlistat. Although signiﬁcant
proportions of orlistat users suffer from adverse events
because of the medication, such as diarrhea, ﬂatulence,
bloating, abdominal pain, and dyspepsia [8], we are
not aware of studies that have linked these side effects
to quality of life. Nevertheless, we believe that because
we used a lifetime perspective while the orlistat treat-
ment lasts for only 1 year, the inﬂuence of side effects
on the cost utility ratios would be minimal.
In conclusion, both a low-calorie diet and low-
calorie diet in combination with orlistat have a higher
cost-effectiveness ratio if no direct effect of BMI on
quality life is assumed and only effects of weight loss
through obesity-related diseases are taken into
account. As a result, especially the addition of orlistat
to the treatment of obesity loses much of its attractive-
ness. We recommend that a diet alone should be the
ﬁrst option for policymakers in combating obesity.
We would like to thank the reviewers for their in depth
review of the article. Furthermore, we would like to thank
our colleague Wien Limburg for critical reading of the article.
Source of ﬁnancial support: This work was funded by the
Dutch Ministry of Health, Welfare and Sports.
References
1 Haslam DW, James WP. Obesity. Lancet 2005;
366:1197–209.
2 Rodgers A, Ezzati M, Vander Hoorn S, et al. Distri-
bution of major health risks: ﬁndings from the Global
Burden of Disease study. PLoS Med 2004;1:e27.
3 Groves T. Pandemic obesity in Europe. BMJ
2006;333:1081.
4 de Hollander AEM, Hoeymans N, Melse JM, et al.
Zorg voor gezondheid—Volksgezondheid Toekomst
Verkenning. 2006. Report No.: RIVM Rapport
270061003. Rijksinstituut voor Volksgezondheid en
Milieu
5 Klein S, Burke LE, Bray GA, et al. Clinical implica-
tions of obesity with speciﬁc focus on cardiovascular
disease: a statement for professionals from the Ameri-
can Heart Association Council on Nutrition, Physical
Activity, and Metabolism: endorsed by the American
College of Cardiology Foundation. Circulation 2004;
110:2952–67.
6 McInnis KJ. Diet, exercise, and the challenge of com-
bating obesity in primary care. J Cardiovasc Nurs
2003;18:93–100;quiz 101–2.
7 Zelissen PM, Mathus-Vliegen EM. Treatment of over-
weight and obesity in adults: proposal for a guideline.
Ned Tijdschr Geneeskd 2004;148:2060–6.
8 Li Z, Maglione M, Tu W, et al. Meta-analysis: phar-
macologic treatment of obesity. Ann Intern Med
2005;142:532–46.
9 Roux L, Kuntz KM, Donaldson C, Goldie SJ. Eco-
nomic evaluation of weight loss interventions in over-
weight and obese women. Obesity (Silver Spring)
2006;14:1093–106.
10 Warren E, Brennan A, Akehurst R. Cost-effectiveness
of sibutramine in the treatment of obesity. Med Decis
Making 2004;24:9–19.
11 Foxcroft DR. Orlistat for the treatment of obesity:
cost utility model. Obes Rev 2005;6:323–8.
12 Hertzman P. The cost effectiveness of orlistat in a
1-year weight-management programme for treating
overweight and obese patients in Sweden: a treatment
responder approach. Pharmacoeconomics 2005;23:
1007–20.
13 Hakim Z, Wolf A, Garrison LP. Estimating the effect
of changes in body mass index on health state prefer-
ences. Pharmacoeconomics 2002;20:393–404.
14 Sach TH, Barton GR, Doherty M, et al. The
relationship between body mass index and health-
related quality of life: comparing the EQ-5D,
EuroQol VAS and SF-6D. Int J Obes (Lond) 2007;
31:189–96.
15 van Baal PH, Hoogenveen RT, de Wit GA, Boshuizen
HC. Estimating health-adjusted life expectancy con-
ditional on risk factors: results for smoking and
obesity. Popul Health Metr 2006;4:14.
16 Westert GP, Jabaau L, Schellevis FG, eds., Morbidity,
performance and quality in primary care: Dutch
general practice on stage. Oxford: Radcliffe Publish-
ing, 2006.
17 Gravelle H, Brouwer W, Niessen L, et al. Discounting
in economic evaluations: stepping forward towards
optimal decision rules. Health Econ 2007;16:307–
17.
18 Brouwer WB, Niessen LW, Postma MJ, Rutten FF.
Need for differential discounting of costs and health
Cost-Effectiveness of a Low-Calorie Diet and Orlistat 1039
effects in cost effectiveness analyses. BMJ 2005;
331:446–8.
19 Hoogenveen RT, de Hollander AEM, van Genugten
MLL. The chronic disease modelling approach. 1998.
Report No.: RIVM Rapport 266750001. Rijksinstit-
uut voor Volksgezondheid en Milieu
20 van Baal PH, Brouwer WB, Hoogenveen RT, Feenstra
TL. Increasing tobacco taxes: a cheap tool to increase
public health. Health Policy 2007;82:142–52.
21 van Baal PH, Feenstra TL, Hoogenveen RT, et al.
Unrelated medical care in life years gained and the cost
utility of primary prevention: in search of a “perfect”
cost-utility ratio. Health Econ 2007;16:421–33.
22 Jacobs-van der Bruggen MA, Bos G, Bemelmans WJ,
et al. Lifestyle interventions are cost-effective in people
with different levels of diabetes risk: results from a
modeling study. Diabetes Care 2007;30:128–34.
23 Oostenbrink JB, Koopmanschap MA, Rutten FFH.
Handleiding voor kostenonderzoek. Methoden voor
economische evaluaties in de gezondheidszorg [Guide-
line for Cost Research. Methods for Economic Evalu-
ations in the Health Care]. Amstelveen: College Voor
Zorgverzekeringen, 2000.
24 Finer N. Low-calorie diets and sustained weight loss.
Obes Res 2001;9(Suppl. 4):S290–4.
25 Anderson JW, Konz EC, Frederich RC, Wood CL.
Long-term weight-loss maintenance: a meta-analysis
of US studies. Am J Clin Nutr 2001;74:579–84.
26 Feenstra TL, Hamberg-van Reenen HH, Hoogenveen
RT, et al. Cost-effectiveness of face-to-face smoking
cessation interventions: a dynamic modeling study.
Value Health 2005;8:178–90.
27 van Genugten ML, Hoogenveen RT, Mulder I, et al.
Future burden and costs of smoking-related disease
in the Netherlands: a dynamic modeling approach.
Value Health 2003;6:494–9.
28 Stouthard MEA, Essink-Bot ML, Bonsel GJ, et al.
Disability Weights for Diseases in the Netherlands.
Rotterdam: Department of Public Health. Erasmus
University, 1997.
29 van Baal PH, Hoeymans N, Hoogenveen RT, et al.
Disability weights for comorbidity and their inﬂuence
on Health-adjusted Life Expectancy. Popul Health
Metr 2006;4:1.
30 Murray CJ, Acharya AK. Understanding DALYs
(disability-adjusted life years). J Health Econ
1997;16:703–30.
31 Melse JM, Essink-Bot ML, Kramers PG, Hoeymans
N. A national burden of disease calculation: dutch
disability-adjusted life-years. Dutch Burden of Disease
Group. Am J Public Health 2000;90:1241–7.
32 Slobbe LCJ, Kommer GJ, Smit JM, et al. Kosten van
ziekten in Nederland. Zorg voor euro’s—1. 2006.
Report No.: RIVM Rapport 270751010. Rijksinstit-
uut voor Volksgezondheid en Milieu.
33 Fenwick E, Claxton K, Sculpher M. Representing
uncertainty: the role of cost-effectiveness acceptability
curves. Health Econ 2001;10:779–87.
34 Lacey LA, Wolf A, O’shea D, et al. Cost-effectiveness
of orlistat for the treatment of overweight and obese
patients in Ireland. Int J Obes (Lond) 2005;29:975–
82.
35 Brouwer WB, van Exel NJ, Baltussen RM, Rutten FF.
A dollar is a dollar is a dollar—or is it? Value Health
2006;9:341–7.
36 Al MJ, Feenstra T, Brouwer WB. Decision makers’
views on health care objectives and budget con-
straints: results from a pilot study. Health Policy
2004;70:33–48.
37 Brouwer WB, Koopmanschap MA. On the economic
foundations of CEA. Ladies and gentlemen, take your
positions! J Health Econ 2000;19:439–59.
38 Meltzer D. Accounting for future costs in medical
cost-effectiveness analysis. J Health Econ, 1997;16:
33–64.
39 Adams KF, Schatzkin A, Harris TB, et al. Overweight,
obesity, and mortality in a large prospective cohort
of persons 50–71 years old. N Engl J Med 2006;
355:763–78.
40 Flegal KM, Graubard BI, Williamson DF, Gail MH.
Excess deaths associated with underweight, over-
weight, and obesity. JAMA 2005;293:1861–7.
41 Saris WH. Very-low-calorie diets and sustained
weight loss. Obes Res 2001;9(Suppl. 4):S295–301.
1040 van Baal et al.
